Focused On-demand Library for Arachidonate 5-lipoxygenase-activating protein

Details

Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


We employ our advanced, specialised process to create targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

PARTNER
Receptor.AI
 
UPACC
P20292

UPID:
AL5AP_HUMAN

ALTERNATIVE NAMES:
FLAP; MK-886-binding protein

ALTERNATIVE UPACC:
P20292; Q5VV04

BACKGROUND:
The Arachidonate 5-lipoxygenase-activating protein, known alternatively as FLAP or MK-886-binding protein, is required for the biosynthesis of leukotrienes by anchoring ALOX5 to the membrane. It binds arachidonic acid, playing a key role in its transfer to ALOX5, and interacts with MK-886 to regulate leukotriene production.

THERAPEUTIC SIGNIFICANCE:
ALOX5AP's involvement in ischemic stroke, through its role in leukotriene biosynthesis, highlights its potential as a target for therapeutic intervention. Exploring the mechanisms by which ALOX5AP influences stroke susceptibility offers a promising avenue for the development of treatments for this and related conditions.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.